Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Jörg Gries

Hans-Christian Militzer

Stefan Koep

Johannes Platzek

Joachim Krüger

Jorma Haβfeld

Kai Lovis

A process for preparing the benzothiophen-2-yl boronate of formula (VI) which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases. 

Process for preparing benzothiophen-2yl boronate

The present application relates to sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate, to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

Substituted sodium-1H-pyrazole-5-olate

The invention relates to a novel process for the preparation of pan-CDK inhibitors of the formula (I), and intermediates of the preparation. 

Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation

Substituted sodium 1H-pyrazol-5-olate

Growing community of inventors

Haan, Germany

Jörg Gries